๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hefei
Clinical trial register · China

Clinical Trials in Hefei, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Anhui Provincial Hospital55 Merck Sharp & Dohme LLC36 Anhui Medical University29 AstraZeneca27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.25
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hefei

875 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Left Ventricular Myocardial Work for Predicting Response to CRT
NCT07319065CRT Non-Response, LBBB, HF - Heart Failure, Healthy Adult
First Hospital of China Medical University
Observational
3,240
Hefei, Wannan, Fuzhou, Guizhou, Xiamen, Lanzhou, Jiangmen, Qinhuangdao
2026-01-01
Not yet open
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
NCT07328919Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc.
Phase 3
138
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2026-01
Recruiting
A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
NCT07240896Wilsons Disease
DSciLab Co., Ltd.
Phase EARLY_PHASE1
18
Hefei
2025-12-31
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2/3
990
Hefei, Chongqing, Fuzhou, Fuzhou Fujian, Guangzhou, Shenzhen, Nanning, Tianjin
2025-12-31
Recruiting
A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)
NCT07310095Crohn Disease
Xian-Janssen Pharmaceutical Ltd.
Phase 4
78
Guangzhou, Hangzhou, Hefei, Shanghai
2025-12-30
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
NCT07143045EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.
Observational
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Meizhou
2025-12-29
Recruiting
An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors
NCT07680257CLDN18.2 Positive Solid Tumors
Celest Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1
18
Hefei
2025-12-27
Recruiting
Noninvasive Real-Time Arterial Waveform Monitoring for Cardiovascular Disease Assessment
NCT07350629Aortic Regurgitation Disease, Aortic Stenosis Disease, Healthy Subjects
Anhui Provincial Cancer Hospital
Observational
15
Hefei
2025-12-26
Recruiting
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
NCT07284134Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
560
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Guangzhou, Meizhou, Shantou
2025-12-24
Recruiting
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061
NCT07241910Healthy Subjects
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 1
40
Hefei
2025-12-23
Recruiting
A Phase โ… /โ…กa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
NCT07228247Solid Tumors, Adult
Hutchmed
Phase 1/2
147
Beijing, Changsha, Guangzhou, Hefei, Shanghai, Shenyang, Zhengzhou
2025-12-16
Recruiting
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
NCT07444307Systemic Lupus Erythematosus (SLE)
Hangzhou Qihan Biotech Co., Ltd.
Phase 1
18
Hefei, Wuhan, Beijing
2025-12-15
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
Eli Lilly and Company
Phase 3
1,035
Beijing, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang
2025-12-15
Recruiting
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
NCT07307235Type 2 Diabetes
Shanghai Zhongshan Hospital
Phase 4
1,316
Hefei, Huizhou, Shenzhen, Harbin, Xinxiang, Wuhan, Changsha, Hengyang
2025-12-13
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
Pfizer
Phase 3
800
Hefei, Beijing, Chongqing, Guangzhou, Meizhou, Nanning, Wuhan, Changsha
2025-12-11
Recruiting
Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma
NCT07099547Biliary Tract Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
60
Hefei
2025-12-02
Recruiting
A Phase I Clinical Trial to Evaluate HECN30227 Injection in Healthy Subjects and Subjects With Chronic Hepatitis B
NCT07771140HBV Infection
Sunshine Lake Pharma Co., Ltd.
Phase 1
78
Hefei
2025-12-02
Recruiting
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
NCT07165951Metastatic Pancreatic Ductal Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
566
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-12-02
Not yet open
Dose-escalation of Rectal Indomethacin for Preventing PEP
NCT07247682Post-ERCP Pancreatitis
The First Affiliated Hospital of Anhui Medical University
Phase 4
1,036
Hefei
2025-12-01
Recruiting
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
NCT07282353Primary Biliary Cholangitis
Cascade Pharmaceuticals, Inc
Phase 3
135
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhanjiang, Nanning
2025-12-01
Recruiting
Clinical Study on the Safety and Efficacy of Temporal Interference Stimulation in the Treatment of Post-Stroke Aphasia
NCT07346378Post-stroke Aphasia
The First Affiliated Hospital of Anhui Medical University
Not applicable
40
Hefei
2025-12-01
Not yet open
A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
NCT07239986Hepatocellular Carcinoma (HCC)
Broadenbio Ltd., Co.
Phase 2
60
Hefei, Shanghai
2025-12
Not yet open
A Clinical Trial of AK152 in Healthy Volunteers and Patients With Alzheimer' s Disease
NCT07301502Alzheimer' s Disease
Akeso
Phase 1
108
Hefei
2025-12
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Hefei, Fuzhou, Xiamen, Guangzhou, Naning, Heilongjiang, Shijiazhuang, Zhengzhou
2025-11-30
Recruiting
Study of Food Effects of VV119 Capsules in Chinese Healthy Volunteers
NCT07240636Healthy Volunteers
Vigonvita Life Sciences
Phase 1
16
Hefei
2025-11-28
Recruiting
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
150
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Nanning, Shijiazhuang
2025-11-27
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO-resistant sqNSCLC
Takeda
Phase 3
600
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Xinxiang
2025-11-26
Recruiting
A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease
NCT07640893Von Willebrand Disease (VWD)
Shanghai RAAS Blood Products Co., Ltd.
Phase 2
24
Changsha, Hefei, Jinan, Nanning, Suzhou, Taiyuan, Tangshan, Tianjin
2025-11-26
Recruiting
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
NCT07328854Nasopharyngeal Carcinoma
Ming-Yuan Chen
Phase 3
346
Hefei, Fuzhou, Guangzhou, Shantou, Zhongshan, Zhuhai, Nanning, Wuzhou
2025-11-20
Recruiting
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
NCT07215585Large B-cell Lymphoma
AstraZeneca
Phase 3
420
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hefei
2025-11-11
Recruiting
The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
NCT07150624Hepatocellular Carcinoma (HCC), Liver Diseases
Anhui Provincial Hospital
Phase 4
96
Hefei
2025-11-10
Recruiting
GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms
NCT07306156EBV Associated Lymphoid Neoplasms
Zhimin Zhai
Phase 1/2
24
Hefei
2025-11-10
Recruiting
Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset
NCT07094763Acute Ischemic Stroke
The First Affiliated Hospital of University of Science and Technology of China
Not applicable
406
Hefei
2025-11-05
Not yet open
Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT
NCT07168278Acute Ischemic Stroke, Large Vessel Occlusion, Tenecteplase, Thrombolysis
The First Affiliated Hospital of University of Science and Technology of China
Phase 3
794
Hefei
2025-11-01
Recruiting
[18F]NIDF PET Imaging in Tau-related Diseases
NCT07306598Neurodegenerative Disease, Alzheimer s Disease, Tauopathies
Tianjin Medical University
Observational
20
Hefei, Qingdao, Tianjin
2025-11-01
Recruiting
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
NCT07187440Fabry Disease
Takeda
Observational
200
Hefei, Beijing, Fuzhou, Hangzhou, Shantou, Shenzhen, Shijiazhuang, Harbin
2025-11-01
Recruiting
Evaluation of the Safety and Effectiveness of CHORDSยฎ Cerebral Protection System During TAVR: DUET Trial
NCT07648693Transcatheter Aortic Valve Replacement (TAVR), Cerebral Vascular Accident (CVA)/Stroke
Resonova (Shanghai) Medtech Limited
Not applicable
240
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanchang, Qingdao
2025-10-31
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751Breast Neoplasms
BioNTech SE
Phase 3
558
Changde, Hefei, Jinan, Lanzhou, Linyi, Nanchang, Nanjing, Neijiang
2025-10-30
Recruiting
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
NCT07330596NSCLC (Advanced Non-small Cell Lung Cancer)
Anhui Provincial Cancer Hospital
Phase 2
96
Hefei
2025-10-30
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb
Phase 2/3
470
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Luoyang, Zhengzhou
2025-10-23
Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
NCT07111546Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd
Phase 2
140
Hefei, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Xiangyang, Changsha
2025-10-20
Recruiting
Personalized iTBS in Real-World Clinical Settings for Schizophrenia
NCT07176468Schizophrenia, Transcranial Magnetic Stimulation
Anhui Medical University
Not applicable
40
Hefei
2025-10-20
Recruiting
KD Treatment for Super-refractory Status Epilepticus
NCT07496749Super-refractory Status Epilepticus
Xuanwu Hospital, Beijing
Not applicable
84
Hefei, Beijing, Fuzhou, Nanning, Guiyang, Haikou, Shijiazhuang, Harbin
2025-10-20
By invitation
Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects
NCT07384104Osteoporosis
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 1
118
Hefei
2025-10-19
By invitation
An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events
NCT07503028T1DM - Type 1 Diabetes Mellitus, Pancreatogenic Diabetes Mellitus
Celregen Therapeutics
Phase EARLY_PHASE1
10
Hefei
2025-10-17
Recruiting
Effects of taVNS Combined With tACS on Adolescents With Non-Suicidal Self-Injury
NCT07486804Non-suicidal Self-injury
Anhui Medical University
Not applicable
90
Hefei
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2025-10-16
Recruiting
CS-121 APOC3 Base Editing in FCS
NCT07176923Familial Chylomicronemia Syndrome (FCS)
CorrectSequence Therapeutics Co., Ltd
Phase EARLY_PHASE1
15
Hefei
2025-10-15
Recruiting
Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects
NCT07150962Overweight or Obesity
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
168
Hefei
2025-10-15
Recruiting
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
NCT07095075Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech Co.
Phase EARLY_PHASE1
36
Bengbu, Hefei, Nanjing, Suzhou, Wenzhou
2025-10-14
Recruiting
Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder
NCT07330648Generalized Anxiety Disorder
Anhui Medical University
Phase 2
216
Hefei
2025-10-10
Recruiting
Reconstruction Kinetics of ฮณฮด T Cells After Unrelated Cord Blood Transplantation
NCT07782684Hematologic Disease and Disorders
Anhui Provincial Hospital
Observational
100
Hefei
2025-10-09
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
675
Hefei, Beijing, Fujian, Fuzhou, Guangzhou, Nanning, Jiamusi, Zhengzhou
2025-10-08
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Pfizer
Phase 2/3
982
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Baoding, Langfang
2025-10-03
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S
Phase 3
1,280
Hefei, Beijing, Changchun, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Harbin
2025-10-02
Active, closed
A Study of Single Dose of LP-003 in Adolescent Subjects
NCT07148557Allergic Diseases
Longbio Pharma
Phase 1/2
6
Hefei
2025-10-01
Not yet open
Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors
NCT07196579Advanced Solid Cancer
TCRx Therapeutics Co.Ltd
Phase 1
30
Hefei
2025-10-01
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
Eli Lilly and Company
Phase 3
1,000
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Lanzhou, Nanjing
2025-09-30
Active, closed
A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.
NCT07557004HR+ / HER2- Advanced Breast Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 1
30
Hefei
2025-09-30
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Pfizer
Phase 3
680
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Wuhan
2025-09-29
Active, closed
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytrudaยฎ in Multiple Resected Solid Tumors
NCT07160335Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
Shanghai Henlius Biotech
Phase 1
174
Hefei, Wuhu, Beijing, Hunan, Fuzhou, Xiamen, Lanzhou, Cangzhou
2025-09-26
Recruiting
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou
2025-09-25
Recruiting
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
NCT07107256Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
246
Fuyang, Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-09-25
Recruiting
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
NCT07312630Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1
19
Hefei
2025-09-25
Active, closed
A Study of IBI3032 in Chinese Participants With Overweight or Obesity
NCT07170319Overweight or Obesity
Innovent Biologics Technology Limited (Shanghai R&D Center)
Phase 1
79
Hefei
2025-09-25
Recruiting
Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
NCT07351487TNBC - Triple-Negative Breast Cancer
First Affiliated Hospital of Zhejiang University
Phase 2
37
Hefei, Shanghai
2025-09-25
Recruiting
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
NCT07331389Overweight Subject, Healthy Subjects
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
111
Hefei
2025-09-24
Recruiting
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
NCT07154264Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals
Phase 2
66
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Yichang, Changsha, Changzhou
2025-09-22
Recruiting
Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
NCT07357623Pulmonary Neuroendocrine Tumor
Shanghai Chest Hospital
Phase 2
96
Hefei, Beijing, Zhengzhou, Shanghai
2025-09-22
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520Non-small Cell Lung Cancer
BioNTech SE
Phase 1/2
880
Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2025-09-22
Recruiting
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
NCT07164170Non-Small Cell Lung Cancer
Abbisko Therapeutics Co, Ltd
Phase 2
86
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2025-09-22
Recruiting
A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects
NCT07102251Healthy Subjects
Sunshine Lake Pharma Co., Ltd.
Phase 1
126
Hefei
2025-09-21
Recruiting
To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer
NCT07195084Non-Small Cell Lung Cancer
Anhui Provincial Cancer Hospital
Not applicable
12
Hefei
2025-09-20
Recruiting
JS207 Combination Therapy in Triple-negative Breast Cancer
NCT07045311Triple-negative Breast Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing
2025-09-17
Not yet open
Multicenter Validation Study on Autism Screening Using a Machine-assisted System
NCT07006948Autism Spectrum Disorder, Early Developmental Impairment, Language Development Disorders
Children's Hospital of Fudan University
Observational
1,000
Hefei, Xiamen, Liuzhou, Harbin, Kunshan, Xi'an, Shanghai, Chengdu
2025-09-15
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471Osteoarthritis
Eli Lilly and Company
Phase 3
800
Baotou, Beijing, Chongqing, Harbin, Hefei, Jinan, Luoyang, Nanjing
2025-09-15
Recruiting
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT07043725HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
544
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Quanzhou, Xiamen, Zhangzhou
2025-09-15
Recruiting
Effect of Vitamin D on Cardiovascular Metabolic Risk in Overweight/Obesity Adolescents in China
NCT07053657Cardiometabolic Risk Factors
Anhui Medical University
Not applicable
130
Anqing, Hefei
2025-09-15
Recruiting
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
NCT07179692Lung Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1
108
Hefei
2025-09-12
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
Bristol-Myers Squibb
Phase 2/3
600
Hefei, Beijing, Fuzhou, Fyzhou, Xiamen, Lanzhou, Nanning, Harbin
2025-09-11
Recruiting
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
NCT06824103Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease
Novartis Pharmaceuticals
Phase 4
50
Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-09-09
Recruiting
Navigated cTBS for the Treatment of Generalized Anxiety Disorder
NCT07121712Generalized Anxiety Disorder
WANG KAI
Not applicable
40
Hefei
2025-09-09
Recruiting
TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease
NCT07295938Mycobacterium Abscessus Pulmonary Disease
Shanghai University of Traditional Chinese Medicine
Phase 2
352
Beijing, Guangdong, Hefei, Nanchang, Shanghai
2025-09-08
Recruiting
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07288554Chronic Obstructive Pulmonary Disease (COPD)
Bambusa Therapeutics
Phase 1
68
Hefei, Guangzhou, Jiangmen, Qingyuan, Xinxiang, Yichang, Xuzhou, Nanchang
2025-09-05
Active, closed
A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNฮฑ for the Treatment of Hepatitis B
NCT07135349Chronic Hepatitis B
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
209
Hefei, Beijing, Sichuan, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi
2025-09-02
Recruiting
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
NCT07093814Glioblastoma
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 1/2
42
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhuhai, Nanning, Jinan
2025-09-02
Recruiting
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT07169994Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
414
Hefei, Fuzhou, Guangzhou, Meizhou, Nanning, Baoding, Harbin, Anyang
2025-09-02
Not yet open
Phase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough Treatment
NCT06773117Cough
Tasly Pharmaceutical Group Co., Ltd
Phase 3
360
Hefei, Chongqing, Guangzhou, Zunyi, Xingtai, Kaifeng, Nanyang, Sanmenxia
2025-09-01
Recruiting
A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
NCT06232083Lung Cancer, Esophageal Cancer, Cervical Cancer
Anhui Provincial Hospital
Phase 1
20
Hefei
2025-09-01
Not yet open
Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection
NCT07156656Type A Aortic Dissection, Organ Failure, Multiple
Shanghai Zhongshan Hospital
Phase 4
236
Hefei, Fuzhou, Guangzhou, Shenzhen, Xi'an, Shanghai
2025-09-01
Recruiting
Intervention Effect of Temporal Interference Stimulation (TIS) on Depressive Disorder
NCT07191392Depressive Disorder, Temporal Interference Stimulation
The Second Hospital of Anhui Medical University
Not applicable
60
Hefei
2025-09-01
Recruiting
Multimodal Clinical Study of Electroconvulsive Therapy and Magnetic Seizure Therapy
NCT07473648Electroconvulsive Therapy, Major Depressive Disorder, Magnetic Seizure Therapy
The Second Hospital of Anhui Medical University
Not applicable
200
Hefei
2025-09-01
Recruiting
Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease
NCT07068438Chronic Bronchitis, COPD (Chronic Obstructive Pulmonary Disease)
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
210
Hefei, Beijing, Changzhou, Suzhou, Wuxi, Xuzhou, Nanchang, Hangzhou
2025-09-01
Not yet open
Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines
NCT07077980Cervical Cancer
Anhui Provincial Hospital
Observational
50
Hefei
2025-09-01
Not yet open
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
666
Bozhou, Chizhou, Hefei, Chongqing, Fuzhou, Zhangzhou, Lanzhou, Foshan
2025-09
Recruiting
Compassion-Based Family Intervention for Adolescents
NCT07138417Emotional Disorder
Beijing HuiLongGuan Hospital
Not applicable
60
Hefei
2025-08-30
Recruiting
Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
NCT07106814Advanced Solid Tumors
Anhui Provincial Hospital
Phase EARLY_PHASE1
36
Hefei
2025-08-29
Recruiting
Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
NCT07146100Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Observational
200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-08-28
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
BeOne Medicines
Phase 3
351
Hefei, Beijing, Xiamen, Anyang, Zhengzhou, Nanjing, Ganzhou, Shenyang
2025-08-27
Recruiting
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
NCT07147348Advanced Solid Tumor
BioNTech SE
Phase 1/2
375
Beijing, Hefei, Henan, Hunan, Shandong, Shanghai, Sichuan, Zhejiang
2025-08-27
Rows per page Showing 201–300 of 875
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hefei?page=3

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 875 of those studies with a site in Hefei.

How many clinical trials are recruiting in Hefei?

512 of the 875 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 137 have not yet opened recruitment, 211 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.